Real-world analysis of first-line afatinib in patients with EGFR-mutant non-small cell lung cancer and brain metastasis: survival and prognostic factors

BACKGROUND: Overall survival (OS) in patients with non-small cell lung cancer (NSCLC) and brain metastases (BMs) is poor. We aimed to identify prognostic factors and ascertain treatment outcomes of first-line afatinib for patients with epidermal growth factor receptor (EGFR)-mutant NSCLC with BM in...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Jehun, Jang, Tae Won, Choi, Chang Min, Kim, Mi Hyun, Lee, Sung Yong, Park, Cheol Kyu, Chang, Yoon Soo, Lee, Kye Young, Kim, Seung Joon, Yang, Sei Hoon, Ryu, Jeong Seon, Lee, Jeong Eun, Lee, Shin Yup, Park, Chan Kwon, Lee, Sang Hoon, Jang, Seung Hun, Yoon, Seong Hoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10326794/
https://www.ncbi.nlm.nih.gov/pubmed/37425421
http://dx.doi.org/10.21037/tlcr-22-832

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10326794/
https://www.ncbi.nlm.nih.gov/pubmed/37425421
http://dx.doi.org/10.21037/tlcr-22-832

Ejemplares similares